Show simple item record

dc.contributor.authorFeliu, Jaume
dc.contributor.authorSafont, M. J.
dc.contributor.authorSalud Salvia, Maria Antonieta
dc.contributor.authorLosa, F.
dc.contributor.authorGarcía-Girón, C.
dc.contributor.authorBosch, Carlos
dc.contributor.authorEscudero, P.
dc.contributor.authorLópez, R.
dc.contributor.authorMadroñal, C.
dc.contributor.authorBolaños, M.
dc.contributor.authorGil, M.
dc.contributor.authorLlombart, A.
dc.contributor.authorCastro-Carpeño, J.
dc.contributor.authorGonzález-Barón, M.
dc.date.accessioned2015-07-09T10:39:46Z
dc.date.issued2010
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/10459.1/48457
dc.description.abstractBACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study. METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of 30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks. RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and 18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome (19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of previous reports in elderly patients. CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy.ca_ES
dc.language.isoengca_ES
dc.publisherNature Publishing Groupca_ES
dc.publisherCancer Research UKca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1038/sj.bjc.6605663ca_ES
dc.relation.ispartofBritish Journal of Cancer, 2010, vol. 102, p. 1468-1473ca_ES
dc.rights(c) Cancer Research UK, 2010ca_ES
dc.rights(c) Nature Publishing Group, 2010ca_ES
dc.subjectcapecitabineca_ES
dc.subjectbevacizumabca_ES
dc.subjectcolorectal neoplasmsca_ES
dc.titleCapecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancerca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.identifier.doihttps://doi.org/10.1038/sj.bjc.6605663
dc.date.embargoEndDate2025-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record